Cruising The Past Cruise News 
The Hollywood Pantages looks like a temple to art. In reality, it’s one of the most efficient profit centers in American theater—and a key node in a national system that turns hit musicals into long-term licensing revenue.
Walk into a current run of Beauty and the Beast or Phantom of the Opera and you’ll see a familiar pattern: a marquee blockbuster, a mostly non-celebrity cast, and a price board that would make a Wall Street trader blink. Rear balcony: about $90 to $100. Front orchestra, center aisles: $700, $800, sometimes nearing $900. For a family of four in the first 10 rows, that’s not a night out; it’s a $2,800 expense line.
This is the new normal for Broadway on the road—and Los Angeles is ground zero.
8 PM Friday Night – Ticket prices from $105 Balcony Row Q to $675 Orchestra Center Row A.
A Palace Built for Movies, Reborn for Profit
The Pantages opened in 1930 as the last great Hollywood movie palace, later becoming the RKO flagship and home to the Academy Awards from 1950 to 1960. After decades as a cinema, it was reborn in the late 1970s and again in the 2000s as the West Coast’s premier legitimate house, now operated by the Nederlander Organization under the “Broadway in Hollywood” brand.
Architecturally, it still sells the old dream: gilded Art Deco, 2,500 seats, a sense of occasion. Economically, it sells something else: scale. Big house, brand-name IP, and a market trained to pay premium prices for “event” theater.
The Road Is the Real Broadway
Here’s the uncomfortable math: for many megamusicals, the road is where the money is made.
Week for week, national tours routinely out-gross their Broadway parents. In recent years, hits like Dear Evan Hansen, Come From Away, Wicked in Los Angeles, and Hamilton in major cities have posted higher weekly tour grosses than in New York. Industry observers have called touring “almost a risk-free investment” compared to the bruising overhead of a Broadway run.
The mechanics are simple. After the house fee and credit-card and marketing deductions, the remaining revenue is split between the local presenter and the producer, often in the 20/80 to 25/75 range. From the producer’s slice, royalties flow to the creators—book, music, lyrics, sometimes direction and choreography. Over the life of a long-running tour, those royalty participants can earn more from the road and international runs than from the Broadway original.
$900 Seats, No Stars
The Pantages today is a showcase for this model. Most touring productions do not feature recognizable “stars.” They are Broadway-caliber ensembles rotating through San Francisco, San Diego, Fresno, and beyond, many under Equity contracts, some not.
Non-Equity tours—Hadestown, Book of Mormon, Chicago, Kinky Boots, and others—have become common nationwide. They allow producers to control labor costs while keeping ticket prices high. The Pantages schedule reflects both tiers: Equity blockbusters alongside non-Equity runs, all priced to maximize yield in a city with few competing legitimate venues.
Dynamic pricing does the rest. Face values start modestly, but premium sections and high-demand performances push top prices into the $800–$900 band on resale and premium channels. The result: a cultural product that feels like mass entertainment but is priced like a luxury good.
L.A. vs. London: The Same Show, Different Planet
Compare this to London’s West End and the American model looks even more extreme.
In London, standard good seats for big musicals often run £20 to £100 (about $26 to $130), with premium center stalls rarely exceeding £300 to £365 ($390 to $475). Day seats and lotteries routinely drop into the £10 to £25 range ($13 to $32). Average ticket prices land around $81 to $127, versus roughly $189 on Broadway.
On Broadway, premium seats for hits can top $500 and, for the biggest names, climb past $1,000; some reports place extreme premiums above $1,500. Fees compound the gap: West End prices generally include booking and facility charges, while Broadway adds service fees at checkout.
Why the difference? Lower operating costs, more venues, more competition, and structural supports like arts subsidies and different labor and healthcare costs. In the U.S., a handful of owners control many key theaters, unions negotiate rigorous terms, and cities rarely subsidize commercial theater. The result is a system optimized for extracting maximum revenue from the smallest number of seats.
The Hidden Winner: Concord Theatricals
Behind the velvet seats and premium orchestra pricing is a second business model: licensing. Concord Theatricals, led by Sean Patrick Flahaven’s team and now enlarged by the 2025 acquisition of Broadway Licensing Global, sits at the center of a vast catalog of plays and musicals. It does not merely license shows once; it monetizes the afterlife of each hit across Broadway, national tours, schools, and community theaters, turning a single success into a long tail of recurring revenue. [61][62][63][64][65]
Concord describes itself as the world’s most significant theatrical company, comprising the catalogs of R&H Theatricals, Tams-Witmark, Samuel French, the Andrew Lloyd Webber Collection, Dramatists Play Service, and Playscripts, plus more than 100 new signings each year. That portfolio includes many of the very titles that fill houses like the Pantages year after year. [64][66][65]
Every time a show tours, the licensing apparatus is working in the background, ensuring that the creators—and the licensing house—earn from each iteration. In that sense, the Pantages is not just a theater; it is a distribution point for a licensing empire that keeps collecting long after the curtain falls.
Is the Pantages the Most Expensive Stop?
It’s hard to declare any single venue “the most expensive” without a comprehensive audit, but the Pantages consistently sits at the top tier for touring pricing in the U.S. Its combination of a 2,500-seat house, a deep-pocketed market, and limited legitimate competition makes it an ideal laboratory for premium pricing.
Ask the obvious question: if a show can command $800 to $900 for front orchestra in Los Angeles, why not in San Francisco, Chicago, or Boston? The answer is market discipline—and the fact that L.A. has been conditioned to pay.
The Picture Behind the Marquee
The real story isn’t just one theater. It’s a national pattern: a shrinking network of legitimate houses, a handful of dominant operators, and a touring circuit that treats cities like L.A., New York, and San Francisco as cash registers for brands created on Broadway and monetized by licensing giants like Concord.
The Pantages is a perfect frame for that picture. It’s a movie palace that learned to monetize live theater better than anyone—an elegant box where the audience pays Broadway-plus prices to see a touring cast that, more often than not, includes no stars at all, while the licensing machinery hums quietly in the background.
Sources
- Wikipedia – Hollywood Pantages Theatre
- Broadway In Hollywood – About the Hollywood Pantages Theatre
- Academy Museum – Hollywood Pantages Theatre
- Clio – Hollywood Pantages Theatre
- LA Conservancy – Pantages Theatre
- Forbes – “Musicals Make More Money on the Road than on Broadway”
- BroadwayWorld – “The Business Behind National Tours and Their Effect on Broadway” (2026)
- Broadway League – Report on economic effects of Broadway tours (2023–2024)
- Actors’ Equity Association – Shows on Tour (Equity vs non-Equity)
- West End vs Broadway pricing summaries (average and premium ticket comparisons)
- Concord Theatricals – “Who We Are” / company overview
- Concord Theatricals – Intro to Licensing / fee structure
- Variety – “Concord Buys Broadway Licensing Global” (2025)
- Theatrical Index – Concord acquires Broadway Licensing Global
- Concord press release – acquisition of Samuel French and formation of Concord Theatricals
- NYU Tisch – profile of Sean Patrick Flahaven and Concord Theatricals
